An Open-label, Multicenter, Phase I Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Relapsed and/or Refractory Solid Cancers
What is the purpose of this trial?
This study is a first-in-human, Phase 1, multicenter, open-label study to determine the safety, tolerability and pharmacokinetics of IGM-8444 as a single agent and in combination with a chemotherapy-based regimen in patients with relapsed and/or refractory solid tumors.
- Trial withIGM Biosciences, Inc.
- Start Date03/05/2021
- End Date08/01/2023
- Last Updated07/15/2021
- Study HIC#2000028780